XML 46 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting

21. Segment Reporting

 

The Company operates as one operating segment, that derives revenue primarily from our principal licensed product, Ameluz®, which is a prescription drug approved for use in PDT using our RhodoLED® Lamps, for the treatment of actinic keratoses. We are currently selling Ameluz® for this indication in the United States under an exclusive license and supply agreement. Ameluz® (including the RhodoLED® Lamps) accounts for approximately 100% of our revenue.

 

The Company’s CODM is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The CODM uses consolidated net income to allocate resources and assesses financial performance by comparing actual results to historical results and previously forecasted financial information.

 

The following table  presents selected financial information with respect to the Company’s single operating segment for the years ended December 31, 2024, and 2023:

 

(in thousands)  December 31, 2024   December 31, 2023 
         
Revenues, net   37,321    34,071 
           
Operating expenses:          
Cost of revenues   18,607    17,444 
Direct sales   9,058    10,940 
Sales support   8,498    9,698 
General and administrative   16,279    18,489 
Research and development   2,089    77 
Other operating expenses   -    100 
Total operating expenses   54,531    56,748 
Loss from operations   (17,210)   (22,677)
Other income (expense), net   (527)   2,560
Loss before income taxes   (17,737)   (20,117)
Income tax expenses   22    14 
Net loss  $(17,759)  $(20,131)